Array BioPharma (NASDAQ:ARRY) reported Q3 2018 earnings this Morning, coming in at ($0.11) per share, beating Wall Street’s estimates of ($0.22) per Share. Revenue for the quarter came in at $66.37 million beating analyst estimates of $28.81 million Recent Insider Trading for Array BioPharma (NASDAQ:ARRY)
- On 4/18/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $15.19 per share and the total transaction amounting to $326,585.00.
- On 4/3/2018 Victor Sandor, Insider, sold 8,689 with an average share price of $15.35 per share and the total transaction amounting to $133,376.15.
- On 3/21/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $16.76 per share and the total transaction amounting to $360,340.00.
- On 3/9/2018 Victor Sandor, Insider, sold 156,016 with an average share price of $17.71 per share and the total transaction amounting to $2,763,043.36.
- On 2/21/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $17.16 per share and the total transaction amounting to $368,940.00.
- On 2/9/2018 Charles M Baum, Director, sold 50,000 with an average share price of $16.90 per share and the total transaction amounting to $845,000.00.
Dividend History for Array BioPharma (NASDAQ:ARRY)
Recent Trading for Array BioPharma (NASDAQ:ARRY) Shares of Array BioPharma closed the previous trading session at 13.62 +0.00 0.00% with 67240 shares trading hands.